On  ||| S:0 E:3 ||| IN
the  ||| S:3 E:7 ||| DT
correlation  ||| S:7 E:19 ||| NN
between  ||| S:19 E:27 ||| IN
histological  ||| S:27 E:40 ||| NN
and  ||| S:40 E:44 ||| CC
cytological  ||| S:44 E:56 ||| JJ
diagnosis ||| S:56 E:65 ||| NN
,  ||| S:65 E:67 ||| ,
and  ||| S:67 E:71 ||| CC
the  ||| S:71 E:75 ||| DT
intrinsic  ||| S:75 E:85 ||| JJ
5  ||| S:85 E:87 ||| CD
subtypes  ||| S:87 E:96 ||| CD
Japanese  ||| S:96 E:105 ||| JJ
General  ||| S:105 E:113 ||| NNP
Rules  ||| S:113 E:119 ||| NNPS
presented  ||| S:119 E:129 ||| VBD
by  ||| S:129 E:132 ||| IN
the  ||| S:132 E:136 ||| DT
Japanese  ||| S:136 E:145 ||| JJ
Breast  ||| S:145 E:152 ||| NNP
Cancer  ||| S:152 E:159 ||| NNP
Society  ||| S:159 E:167 ||| NNP
have  ||| S:167 E:172 ||| VBP
been  ||| S:172 E:177 ||| VBN
long  ||| S:177 E:182 ||| JJ
time  ||| S:182 E:187 ||| NN
applied  ||| S:187 E:195 ||| VBN
in  ||| S:195 E:198 ||| IN
Japan ||| S:198 E:203 ||| NNP
.  ||| S:203 E:205 ||| .
This  ||| S:205 E:210 ||| DT
classification  ||| S:210 E:225 ||| JJ
uniquely  ||| S:225 E:234 ||| NN
adds  ||| S:234 E:239 ||| VBZ
subtypes  ||| S:239 E:248 ||| VBN
into  ||| S:248 E:253 ||| IN
the  ||| S:253 E:257 ||| DT
group  ||| S:257 E:263 ||| NN
of  ||| S:263 E:266 ||| IN
invasive  ||| S:266 E:275 ||| FW
ductal  ||| S:275 E:282 ||| FW
carcinomas  ||| S:282 E:293 ||| FW
( ||| S:293 E:294 ||| -LRB-
IDC ||| S:294 E:297 ||| NNP
)  ||| S:297 E:299 ||| -RRB-
and  ||| S:299 E:303 ||| CC
reported  ||| S:303 E:312 ||| VBD
to  ||| S:312 E:315 ||| TO
be  ||| S:315 E:318 ||| VB
correlated  ||| S:318 E:329 ||| VBN
to  ||| S:329 E:332 ||| TO
patients ||| S:332 E:340 ||| NNS
'  ||| S:340 E:342 ||| POS
clinical  ||| S:342 E:351 ||| JJ
course ||| S:351 E:357 ||| NN
.  ||| S:357 E:359 ||| .
The  ||| S:359 E:363 ||| DT
latest  ||| S:363 E:370 ||| JJS
St.  ||| S:370 E:374 ||| NNP
Gallen  ||| S:374 E:381 ||| NNP
consensus  ||| S:381 E:391 ||| NN
meeting  ||| S:391 E:399 ||| NN
reported  ||| S:399 E:408 ||| VBD
the  ||| S:408 E:412 ||| DT
use  ||| S:412 E:416 ||| NN
of  ||| S:416 E:419 ||| IN
5  ||| S:419 E:421 ||| CD
molecules ||| S:421 E:430 ||| NNS
,  ||| S:430 E:432 ||| ,
and  ||| S:432 E:436 ||| CC
introduced  ||| S:436 E:447 ||| VBD
alternative  ||| S:447 E:459 ||| JJ
definition  ||| S:459 E:470 ||| NN
in  ||| S:470 E:473 ||| IN
the  ||| S:473 E:477 ||| DT
breast  ||| S:477 E:484 ||| NN
cancer  ||| S:484 E:491 ||| NN
classification ||| S:491 E:505 ||| NN
.  ||| S:505 E:507 ||| .
The  ||| S:507 E:511 ||| DT
purpose  ||| S:511 E:519 ||| NN
of  ||| S:519 E:522 ||| IN
this  ||| S:522 E:527 ||| DT
study  ||| S:527 E:533 ||| NN
is  ||| S:533 E:536 ||| VBZ
to  ||| S:536 E:539 ||| TO
relate  ||| S:539 E:546 ||| VB
the  ||| S:546 E:550 ||| DT
Japanese  ||| S:550 E:559 ||| JJ
subgrouping  ||| S:559 E:571 ||| NN
of  ||| S:571 E:574 ||| IN
IDC  ||| S:574 E:578 ||| NNP
with  ||| S:578 E:583 ||| IN
the  ||| S:583 E:587 ||| DT
5  ||| S:587 E:589 ||| CD
subtypes  ||| S:589 E:598 ||| NNS
and  ||| S:598 E:602 ||| CC
to  ||| S:602 E:605 ||| TO
investigate  ||| S:605 E:617 ||| VB
whether  ||| S:617 E:625 ||| IN
these  ||| S:625 E:631 ||| DT
classifications  ||| S:631 E:647 ||| NNS
could  ||| S:647 E:653 ||| MD
predict  ||| S:653 E:661 ||| VB
early  ||| S:661 E:667 ||| JJ
and  ||| S:667 E:671 ||| CC
late  ||| S:671 E:676 ||| JJ
recurrence  ||| S:676 E:687 ||| NN
and  ||| S:687 E:691 ||| CC
whether  ||| S:691 E:699 ||| IN
cytological  ||| S:699 E:711 ||| JJ
diagnosis  ||| S:711 E:721 ||| NN
is  ||| S:721 E:724 ||| VBZ
influenced  ||| S:724 E:735 ||| VBN
by  ||| S:735 E:738 ||| IN
the  ||| S:738 E:742 ||| DT
tumor  ||| S:742 E:748 ||| NN
phenotypes ||| S:748 E:758 ||| NN
.  ||| S:758 E:760 ||| .
Analyzing  ||| S:760 E:770 ||| VBG
127  ||| S:770 E:774 ||| CD
cases ||| S:774 E:779 ||| NNS
,  ||| S:779 E:781 ||| ,
we  ||| S:781 E:784 ||| PRP
observed  ||| S:784 E:793 ||| VBD
that  ||| S:793 E:798 ||| IN
the  ||| S:798 E:802 ||| DT
Ki-67  ||| S:802 E:808 ||| JJ
labeling  ||| S:808 E:817 ||| JJ
index  ||| S:817 E:823 ||| NN
( ||| S:823 E:824 ||| -LRB-
LI ||| S:824 E:826 ||| NNP
)  ||| S:826 E:828 ||| -RRB-
of  ||| S:828 E:831 ||| IN
the  ||| S:831 E:835 ||| DT
5  ||| S:835 E:837 ||| CD
subtypes ||| S:837 E:845 ||| NN
,  ||| S:845 E:847 ||| ,
luminal  ||| S:847 E:855 ||| VBG
A ||| S:855 E:856 ||| DT
,  ||| S:856 E:858 ||| ,
luminal  ||| S:858 E:866 ||| CD
B-Her2-- ||| S:866 E:874 ||| CD
/ ||| S:874 E:875 ||| CD
-  ||| S:875 E:877 ||| :
Her2+ ||| S:877 E:882 ||| CD
,  ||| S:882 E:884 ||| ,
Her2-subtype  ||| S:884 E:897 ||| NNP
and  ||| S:897 E:901 ||| CC
basal-like ||| S:901 E:911 ||| JJ
,  ||| S:911 E:913 ||| ,
is  ||| S:913 E:916 ||| VBZ
increased  ||| S:916 E:926 ||| VBN
in  ||| S:926 E:929 ||| IN
this  ||| S:929 E:934 ||| DT
order ||| S:934 E:939 ||| NN
.  ||| S:939 E:941 ||| .
Though  ||| S:941 E:948 ||| IN
the  ||| S:948 E:952 ||| DT
Japanese  ||| S:952 E:961 ||| JJ
histological  ||| S:961 E:974 ||| JJ
groups ||| S:974 E:980 ||| NNS
,  ||| S:980 E:982 ||| ,
papillotubular ||| S:982 E:996 ||| NN
,  ||| S:996 E:998 ||| ,
solid-tubular  ||| S:998 E:1012 ||| JJ
and  ||| S:1012 E:1016 ||| CC
scirrhous ||| S:1016 E:1025 ||| NN
,  ||| S:1025 E:1027 ||| ,
included  ||| S:1027 E:1036 ||| VBD
more  ||| S:1036 E:1041 ||| JJR
or  ||| S:1041 E:1044 ||| CC
less  ||| S:1044 E:1049 ||| RBR
those  ||| S:1049 E:1055 ||| DT
subtypes ||| S:1055 E:1063 ||| NN
,  ||| S:1063 E:1065 ||| ,
the  ||| S:1065 E:1069 ||| DT
luminal  ||| S:1069 E:1077 ||| JJ
types  ||| S:1077 E:1083 ||| NNS
were  ||| S:1083 E:1088 ||| VBD
more  ||| S:1088 E:1093 ||| RBR
represented  ||| S:1093 E:1105 ||| VBN
in  ||| S:1105 E:1108 ||| IN
papillotubular  ||| S:1108 E:1123 ||| NN
and  ||| S:1123 E:1127 ||| CC
scirrhous  ||| S:1127 E:1137 ||| JJ
subtypes ||| S:1137 E:1145 ||| NN
,  ||| S:1145 E:1147 ||| ,
and  ||| S:1147 E:1151 ||| CC
the  ||| S:1151 E:1155 ||| DT
solid-tubular  ||| S:1155 E:1169 ||| JJ
type  ||| S:1169 E:1174 ||| NN
in  ||| S:1174 E:1177 ||| IN
non  ||| S:1177 E:1181 ||| JJ
luminal  ||| S:1181 E:1189 ||| JJ
subtypes ||| S:1189 E:1197 ||| NN
.  ||| S:1197 E:1199 ||| .
The  ||| S:1199 E:1203 ||| DT
Ki-67  ||| S:1203 E:1209 ||| NNP
LI  ||| S:1209 E:1212 ||| NNP
14 ||| S:1212 E:1214 ||| CD
%  ||| S:1214 E:1216 ||| NN
served  ||| S:1216 E:1223 ||| VBN
as  ||| S:1223 E:1226 ||| IN
a  ||| S:1226 E:1228 ||| DT
cutoff  ||| S:1228 E:1235 ||| NN
for  ||| S:1235 E:1239 ||| IN
differentiating  ||| S:1239 E:1255 ||| JJ
invasive  ||| S:1255 E:1264 ||| NN
from  ||| S:1264 E:1269 ||| IN
non-invasive  ||| S:1269 E:1282 ||| JJ
ductal  ||| S:1282 E:1289 ||| JJ
carcinomas ||| S:1289 E:1299 ||| NN
.  ||| S:1299 E:1301 ||| .
Breast  ||| S:1301 E:1308 ||| JJ
cancers  ||| S:1308 E:1316 ||| NNS
recur  ||| S:1316 E:1322 ||| VBN
within  ||| S:1322 E:1329 ||| IN
5  ||| S:1329 E:1331 ||| CD
years  ||| S:1331 E:1337 ||| NNS
after  ||| S:1337 E:1343 ||| IN
the  ||| S:1343 E:1347 ||| DT
clinical  ||| S:1347 E:1356 ||| JJ
onset  ||| S:1356 E:1362 ||| NN
when  ||| S:1362 E:1367 ||| WRB
the  ||| S:1367 E:1371 ||| DT
Ki-67  ||| S:1371 E:1377 ||| NNP
LI  ||| S:1377 E:1380 ||| NNP
exceeded  ||| S:1380 E:1389 ||| VBD
14 ||| S:1389 E:1391 ||| CD
% ||| S:1391 E:1392 ||| NN
.  ||| S:1392 E:1394 ||| .
These  ||| S:1394 E:1400 ||| DT
data  ||| S:1400 E:1405 ||| NNS
suggest  ||| S:1405 E:1413 ||| VBP
that ||| S:1413 E:1417 ||| RB
,  ||| S:1417 E:1419 ||| ,
( ||| S:1419 E:1420 ||| -LRB-
1 ||| S:1420 E:1421 ||| LS
)  ||| S:1421 E:1423 ||| -RRB-
the  ||| S:1423 E:1427 ||| DT
intrinsic  ||| S:1427 E:1437 ||| JJ
subtyping  ||| S:1437 E:1447 ||| NN
is  ||| S:1447 E:1450 ||| VBZ
an  ||| S:1450 E:1453 ||| DT
accurate  ||| S:1453 E:1462 ||| JJ
modality  ||| S:1462 E:1471 ||| NN
in  ||| S:1471 E:1474 ||| IN
diagnosing  ||| S:1474 E:1485 ||| JJ
breast  ||| S:1485 E:1492 ||| NN
cancers ||| S:1492 E:1499 ||| NNS
,  ||| S:1499 E:1501 ||| ,
( ||| S:1501 E:1502 ||| -LRB-
2 ||| S:1502 E:1503 ||| LS
)  ||| S:1503 E:1505 ||| -RRB-
it  ||| S:1505 E:1508 ||| PRP
can  ||| S:1508 E:1512 ||| MD
predict  ||| S:1512 E:1520 ||| VB
the  ||| S:1520 E:1524 ||| DT
recurrence  ||| S:1524 E:1535 ||| JJ
duration ||| S:1535 E:1543 ||| NN
,  ||| S:1543 E:1545 ||| ,
( ||| S:1545 E:1546 ||| -LRB-
3 ||| S:1546 E:1547 ||| LS
)  ||| S:1547 E:1549 ||| -RRB-
the  ||| S:1549 E:1553 ||| DT
solid-tubular  ||| S:1553 E:1567 ||| JJ
type  ||| S:1567 E:1572 ||| NN
of  ||| S:1572 E:1575 ||| IN
the  ||| S:1575 E:1579 ||| DT
Japanese  ||| S:1579 E:1588 ||| JJ
classification  ||| S:1588 E:1603 ||| NN
is  ||| S:1603 E:1606 ||| VBZ
likely  ||| S:1606 E:1613 ||| RB
an  ||| S:1613 E:1616 ||| DT
aggressive  ||| S:1616 E:1627 ||| JJ
form  ||| S:1627 E:1632 ||| NN
among  ||| S:1632 E:1638 ||| IN
breast  ||| S:1638 E:1645 ||| JJ
cancers ||| S:1645 E:1652 ||| NNS
,  ||| S:1652 E:1654 ||| ,
and  ||| S:1654 E:1658 ||| CC
( ||| S:1658 E:1659 ||| -LRB-
4 ||| S:1659 E:1660 ||| LS
)  ||| S:1660 E:1662 ||| -RRB-
the  ||| S:1662 E:1666 ||| DT
cytological  ||| S:1666 E:1678 ||| JJ
diagnosis  ||| S:1678 E:1688 ||| NN
is  ||| S:1688 E:1691 ||| VBZ
presently  ||| S:1691 E:1701 ||| RB
a  ||| S:1701 E:1703 ||| DT
powerful  ||| S:1703 E:1712 ||| JJ
tool  ||| S:1712 E:1717 ||| NN
in  ||| S:1717 E:1720 ||| IN
determining  ||| S:1720 E:1732 ||| VBG
malignancy ||| S:1732 E:1742 ||| NN
.  ||| S:1742 E:1744 ||| .
